Eleazar Sukenik

Clearmind Medicine Announces Positive Pre-Clinical Results for Cocaine Addiction Treatment

Retrieved on: 
Tuesday, June 7, 2022
Eleazar Sukenik, MEAI, CSE, Research, Cocaine, News, Opioid addiction treatment in United States prisons, Gonda, Laboratory rat, Rat, Therapy, Male, GLOBE, Acquisition, CPP, Conditioned place preference, FSE, OTC Markets Group, Bar-Ilan University, Hebrew University of Jerusalem, Pharmaceutical industry, Drug

VANCOUVER, June 07, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced positive pre-clinical results for its treatment for cocaine addiction using MEAI, its novel psychedelic molecule.

Key Points: 
  • VANCOUVER, June 07, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (Clearmind or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced positive pre-clinical results for its treatment for cocaine addiction using MEAI, its novel psychedelic molecule.
  • While effective treatments for opioid addictions have been available, this could be the first dedicated treatment for cocaine addiction, which is a global crisis.
  • Rats previously conditioned with cocaine received either cocaine (at 15mg/kg) or MEAI at doses of 2.5, 5, 10 and 20 mg/kg.
  • The results followed Clearmind's recent news regarding filing a provisional patent application related to cocaine addiction.

Clearmind Medicine and SciSparc Collaboration Yields Another Patent Application for Cocaine Addiction Treatment

Retrieved on: 
Thursday, June 2, 2022
Eleazar Sukenik, MEAI, Frankfurt Stock Exchange, Death, CSE, Research, Cocaine, OTC, Canadian Securities Exchange, Patent, Central nervous system, Prison, National Institute on Drug Abuse, Status epilepticus, Autism, Pain, Therapy, GLOBE, Justice, CBD, Violence, Tourette syndrome, Acquisition, NASDAQ, Obstructive sleep apnea, Alzheimer's disease, FSE, Agitation, OTC Markets Group, Substance abuse, Bar-Ilan University, National Institute, Hebrew University of Jerusalem, THC, Pharmaceutical industry, Drug

VANCOUVER, June 02, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced it has filed a provisional patent application related to cocaine addiction.The move results from the company’s recently launched collaboration with SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system ("SciSparc").

Key Points: 
  • The patent application refers to the proprietary combination of Clearmind's MEAI, a novel proprietary psychedelic treatment for addiction, with SciSparc's CannAmide.
  • The two companies plan to pursue a pre-clinical trial to examine the effect of the combination treatment as an anti-reward agent for treating cocaine addiction.
  • Dr. Adi Zuloff- Shani continued, Since the successful initial results demonstrated potential treatment for cocaine abuse, we intend to expand the collaboration with SciSparc and explore the effect of our combination treatment for cocaine.
  • Although cocaine addiction is an established epidemic worldwide, it has no dedicated treatment in the market, which makes our candidate treatment highly attractive.

Clearmind Medicine Granted Patent Approval for Psychedelic- Based Alcohol Substitute in India

Retrieved on: 
Wednesday, June 1, 2022
The Company, Eleazar Sukenik, MEAI, Frankfurt Stock Exchange, CSE, Research, OTC, Canadian Securities Exchange, Patent, Therapy, GLOBE, Acquisition, FSE, OTC Markets Group, Family, Bar-Ilan University, Hebrew University of Jerusalem, Trademark, Generic drug, Pharmaceutical industry

VANCOUVER, June 01, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, has been granted patent approval from the Office of the Controller-General of Patents, Designs and Trademarks in India. The patent refers to the company’s proprietary MEAI-based alcohol substitute patent family.

Key Points: 
  • The patent refers to the companys proprietary MEAI-based alcohol substitute patent family.
  • "Our innovation continues to gain global recognition, this time by the Indian patent office."
  • Clearmind is the sole owner of a family of patents concerning a synthetic substance as a replacement for alcohol.
  • Clearmind was previously also granted patents for this application in Europe and has pending applications in the United States and China for this patent family.

Hebrew University of Jerusalem and Libra Group Launch $1.25 Million 10-Year Fellowship Program for Graduate Students

Retrieved on: 
Thursday, June 2, 2022
Eleazar Sukenik, Faculty, Environmental science, External relations of Jersey, Political science, Program, Nobel Prize, Research, UC Davis College of Agricultural and Environmental Sciences, Biotechnology, Harvard University Advanced Leadership Initiative, Computer Sciences, ESG, The Intern Group, Aviation, Social responsibility, American Friends of the Hebrew University, International relations, Libra Group, Partnership, Group, Welfare, American Friends, List of life sciences, Libra, University, Investment, Student, Nano, Friends, Fields Medal, AFHU, HU, Hebrew University of Jerusalem, Medicine

NEW YORK and JERUSALEM, June 2, 2022 /PRNewswire/ --Today the Libra Group and the Hebrew University of Jerusalem (HU) announced the creation of Libra Fellows at Hebrew University, a 10-year program for graduate students.

Key Points: 
  • NEW YORK and JERUSALEM, June 2, 2022 /PRNewswire/ --Today the Libra Group and the Hebrew University of Jerusalem (HU) announced the creation of Libra Fellows at Hebrew University, a 10-year program for graduate students.
  • Since 2016, Libra Group has partnered with Hebrew University to support students in pursing graduate research and undergraduate exchange programs.
  • We are proud to support Hebrew University in launching this program to benefit leaders and innovators both within Israel and beyond its borders."
  • In addition to the fellowship program, the Libra Group will also invite HU students to apply each year for the company's global internship program.

Hebrew University of Jerusalem and Libra Group Launch $1.25 Million 10-Year Fellowship Program for Graduate Students

Retrieved on: 
Thursday, June 2, 2022
Eleazar Sukenik, Faculty, View, Environmental science, External relations of Jersey, Political science, Program, Nobel Prize, Research, UC Davis College of Agricultural and Environmental Sciences, Biotechnology, Harvard University Advanced Leadership Initiative, Computer Sciences, ESG, The Intern Group, Aviation, Social responsibility, American Friends of the Hebrew University, International relations, Libra Group, Partnership, Group, Welfare, American Friends, List of life sciences, Libra, University, Investment, Multimedia, Student, Nano, Friends, Fields Medal, AFHU, HU, Hebrew University of Jerusalem, Medicine

NEW YORK and JERUSALEM, June 2, 2022 /PRNewswire/ --Today the Libra Group and the Hebrew University of Jerusalem (HU) announced the creation of Libra Fellows at Hebrew University, a 10-year program for graduate students.

Key Points: 
  • NEW YORK and JERUSALEM, June 2, 2022 /PRNewswire/ --Today the Libra Group and the Hebrew University of Jerusalem (HU) announced the creation of Libra Fellows at Hebrew University, a 10-year program for graduate students.
  • Since 2016, Libra Group has partnered with Hebrew University to support students in pursing graduate research and undergraduate exchange programs.
  • We are proud to support Hebrew University in launching this program to benefit leaders and innovators both within Israel and beyond its borders."
  • In addition to the fellowship program, the Libra Group will also invite HU students to apply each year for the company's global internship program.

MediWound Announces CEO Transition

Retrieved on: 
Tuesday, May 17, 2022
Compugen (Israeli company), Contract, Government, Initial public offering, Review, Foundation, Burns, Mathematics, Entrepreneurship, Hebrew University of Jerusalem, Debridement, Investment, Bromelain (pharmacology), COVID-19, Research, Eleazar Sukenik, Form 20-F, Board, Growth, GLOBE, Company, General manager, Burn, FDA, European Medicines Agency, Regeneration, Phrase, Partner (business rank), Annual report, Nasdaq, Leadership, Patient, TASE, Safety, Union, Board of directors, CBI, Development, CCTS, BARDA, CEO, Management, Pharmaceutical industry, Director, Tel Aviv University, Physics, Economics, Chemistry

YAVNE, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the appointment of Ofer Gonen as Chief Executive Officer (CEO) of MediWound as of June 30, 2022, succeeding Sharon Malka, who will join the Company's Board of Directors. Ofer Gonen has been a board member in MediWound and the CEO of Clal Biotechnology Industries, Ltd. (“CBI”), MediWound’s largest shareholder, for the past 5 years.

Key Points: 
  • Ofer Gonen, current Board member and CEO of Clal Biotechnology Industries Ltd., appointed as New CEO Effective June 30
    Will replace current CEO Sharon Malka, who will join the Board of Directors
    YAVNE, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the appointment of Ofer Gonen as Chief Executive Officer (CEO) of MediWound as of June 30, 2022, succeeding Sharon Malka, who will join the Company's Board of Directors.
  • Ofer Gonen has been a board member in MediWound and the CEO of Clal Biotechnology Industries, Ltd. (CBI), MediWounds largest shareholder, for the past 5 years.
  • His extensive managerial experience in leading companies, global networking and deep understanding of MediWounds strengths and potential, position him uniquely to lead MediWound in its further development.
  • Sharon Malka, CEO of MediWound stated, I have accomplished my goal as CEO of positioning the Company for long-term success and a strong future.

TrustPeers appoints new CTO to accelerate technological innovation

Retrieved on: 
Monday, May 9, 2022
Rafael Advanced Defense Systems, Eleazar Sukenik, Algorithm, Hotel manager, Doctor of Philosophy, TEL, Hebrew University of Jerusalem, Organization, MIT, Knowledge, Machine learning, Incident, View, Software as a service, Solution, Technology, Multimedia, Risk management, Instrumentation

TEL AVIV, Israel, May 9, 2022 /PRNewswire/ -- TrustPeers proprietary technology revolutionizes Incident Response (IR) solutions with its real-time and adaptive platform.

Key Points: 
  • TEL AVIV, Israel, May 9, 2022 /PRNewswire/ -- TrustPeers proprietary technology revolutionizes Incident Response (IR) solutions with its real-time and adaptive platform.
  • He is joining TrustPeers to promote the company's long-term vision of taking Incident Response from a manual labor liability to a military-grade autonomous defense capability at the organization's hands.
  • Prior to joining TrustPeers, Lior worked in Rafael Advanced Defense Systems as Head of Department and Research Associate.
  • As an Autonomous AI Decision Making experts he will contribute to the revolutionary impact that TrustPeers is making on the Incident Response sphere".

Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics

Retrieved on: 
Wednesday, April 27, 2022
Euronext Growth, Patent, CEO, Glioblastoma, Hebrew University of Jerusalem, LLC, U.S. Securities and Exchange Commission, Lymphatic system, Security (finance), IPSC, NASDAQ, Research, Annual report, Nasdaq, UCSF, Private Securities Litigation Reform Act, HCC, GMP, GLOBE, YouTube, INSERM, Patient, Gene editing, Cornerstone, LinkedIn, Technology, Social media, Immune system, Laboratory, INKC, CAR, Forward-looking statement, University of California, San Francisco, NK, Special-purpose acquisition company, Partnership, University, Exercise, Ink, Therapy, Eleazar Sukenik, Cancer, Fine chemical, Pharmaceutical industry, Vaccine, NCR1, Cellectis, Isleworth

Concurrent with the business combination agreement, Cellectis received a $20 million convertible note in payment of the upfront collaboration consideration provided for pursuant to the research collaboration and non-exclusive license agreement entered between Cellectis and Cytovia in February 2021.

Key Points: 
  • Concurrent with the business combination agreement, Cellectis received a $20 million convertible note in payment of the upfront collaboration consideration provided for pursuant to the research collaboration and non-exclusive license agreement entered between Cellectis and Cytovia in February 2021.
  • Cellectis and Cytovias research and development collaboration:
    In February 2021, Cellectis and Cytovia entered into a strategic research and development collaboration to develop TALEN gene-edited iPSC NK and CAR-NK cells.
  • In November 2021, Cellectis and Cytovia extended their collaboration to include new CAR target and development in China by Cytovias strategic partner, CytoLynx Therapeutics.
  • Financial terms of the collaboration include the $20 million convertible note as well as up to $805 million of development, regulatory, and sales milestones and single-digit royalty payments on the net sales of all partnered products commercialized by Cytovia.

Andrei Damian, M.D., F.A.C.C. is recognized by Continental Who's Who

Retrieved on: 
Monday, April 18, 2022
Hebrew University of Jerusalem, IRMS, Medicine, Continental, Hospital, Education, Patient, American College of Cardiology, American College, CVC, FACC, Multimedia, Acquisition, Eleazar Sukenik, Online shopping, Phoenix

He has years of experience creating healthcare models that benefit the consumer and allow them to pay less for high-quality care.

Key Points: 
  • He has years of experience creating healthcare models that benefit the consumer and allow them to pay less for high-quality care.
  • Dr. Damian has expertise in creating value-added contracts while actively collaborating on healthcare models.
  • To obtain his education, Dr. Damian attended the Hebrew University of Jerusalem, where he earned a Doctor of Medicine degree.
  • Dr. Damian was the President of IRMS in Phoenix, AZ, from 2012-2016, becoming a board member and healthcare consultant in 2012.

Collaboration between IQM Quantum Computers, Hebrew University of Jerusalem and Bar-Ilan University to accelerate quantum technology research.

Retrieved on: 
Thursday, April 7, 2022
Education, Semiconductor, Technology, Nanotechnology, Software, University, Hardware, Columbia University Physics Department, HUJI, COO, Quantum, University, Multimedia, HU, Bar-Ilan University, Research, Social responsibility, Faculty, Durham University Department of Physics, Hebrew University of Jerusalem, IQM, Eleazar Sukenik, Humanities, Fields Medal, Technology, Machine learning, Computer, Student, Aviation, Department, Education, HPC, VTT, Microscope, Management

IQM Quantum Computers , Hebrew University of Jerusalem and Bar-Ilan University have started a research cooperation on quantum technologies, with IQM providing commercial-grade quantum-computing hardware components to both universities.

Key Points: 
  • IQM Quantum Computers , Hebrew University of Jerusalem and Bar-Ilan University have started a research cooperation on quantum technologies, with IQM providing commercial-grade quantum-computing hardware components to both universities.
  • View the full release here: https://www.businesswire.com/news/home/20220407005722/en/
    IQM, the Pan-European leader in quantum computers, Hebrew University of Jerusalem and Bar-Ilan University, among the leading universities in the world, announced today cooperation in quantum computing focused on research, exchange of know-how and quantum hardware.
  • - IQM has delivered the first milestone of the Finnish quantum computer co-innovation project with VTT; the 5-qubit quantum computer is now operational.
  • About the Hebrew University of Jerusalem:
    The Hebrew University of Jerusalem (HUJI) is Israels leading academic and research institution, serving over 25,000 students from some 80 countries on 6 campuses.